Corticosteroid treatment increases survival of preterm infants within hours

[PRESS RELEASE 2017-05-15]  The effects of corticosteroid treatments on pregnant women facing preterm delivery to prevent infant death and morbidity have been thought to develop gradually over days. However, a new study by researchers at Karolinska Institutet and colleagues in the European EPICE project – coordinated by Inserm, Paris – suggests that survival and health gains for very preterm infants may occur within hours.

Hundreds of thousands of pregnant women in Europe deliver preterm every year. Even if survival nowadays is the most probable outcome, preterm birth is still one of the major causes of death in children under the age of 5. To prepare the foetus for breathing air and increase chances of survival after birth, corticosteroid treatment is given to pregnant women at risk of preterm delivery. So far, the protective effect of corticosteroids before birth has been thought to develop gradually over days. A large European study – published in JAMA Pediatrics – provides new knowledge, however, indicating an immediate effect.

“Our study finds that antenatal (before birth) corticosteroids given to pregnant women only hours before delivery were associated with a survival advantage for their infants”, says Mikael Norman, lead author, neonatologist and professor at Karolinska Institutet’s Department of Clinical Science, Intervention and Technology in Stockholm, Sweden.

Mikael Norman and colleagues on the EPICE (Effective Perinatal Intensive Care in Europe) research project have studied outcomes in over 4,500 very preterm infants, born at 24 to 31 weeks of gestation (excluding multiple pregnancies and severe congenital malformations) in 11 countries across Europe. In this cohort, 15 per cent of the pregnant women were not exposed to antenatal corticosteroids. 21 per cent of the unexposed infants died after birth.

Infants born already 3 hours after corticosteroid administration to the mother had significantly lower mortality than those not exposed to the treatment, and corticosteroid administration 6 to 12 hours before birth was associated with halved risks of infant death.

“Given the current concept of a slow effect, pregnant women at immediate risk of preterm delivery may not receive corticosteroid treatment because it is considered futile”, says Dr Norman. “Also our results can provide reassurance for clinicians or parents in situations where it is not possible to wait a day or two to reach the full effect of corticosteroid treatment because of the need for action to reduce or stop ongoing morbidity in the pregnant woman and her foetus”, he continues.

In the study, antenatal corticosteroid treatment was also associated with a lower risk of severe neonatal morbidity such as bleedings in the brain. This reduction in the risk was associated with longer administration-to-birth intervals.

“Our findings challenge current beliefs that very short exposures to antenatal steroids before delivery have no effect, and suggest that encouraging the administration of antenatal corticosteroids to pregnant women when delivery is very imminent could result in substantial survival and health gains for very preterm infants” says Jennifer Zeitlin, principal investigator of the EPICE study and researcher at Inserm (French National Institute of Health and Medical Research), Paris, France.

The research received funding from the European Union's Seventh Framework Program, the French Institute of Public Health Research/Institute of Public Health and its partners, the National Research Agency through the French Equipex Program of Investments in the Future, the PremUp Foundation in France, the Polish Ministry of Science and Higher Education, regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, and Karolinska University Hospital in Sweden.

Publication: “Association of short antenatal corticosteroid administration-to-birth intervals with survival and morbidity in very preterm infants – results from the EPICE cohort”. Mikael Norman, Aurelie Piedvache, Klaus Børch, Lene Drasbek Huusom, Anna-Karin Edstedt Bonamy, Elizabeth A. Howell, Pierre-Henri Jarreau, Rolf F. Maier, Ole Pryds, Liis Toome, Heili Varendi, Tom Weber, Emilija Wilson, Arno VanHeijst, Marina Cuttini, Jan Mazela, Henrique Barros, Patrick Van Reempts, Elizabeth Draper, Jennifer Zeitlin on behalf of the EPICE Research Group. JAMA Pediatrics , online 15 May 2017, doi:10.1001/jamapediatrics.2017.0602.

For more information, please contact:
Mikael Norman, professor/senior physician
Department of Clinical Science, Intervention and Technology
Karolinska Institutet
Phone: +46 (0)8 585 810 65
Mobile: +46 (0)700 021 007

Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.


About Us

KAROLINSKA INSTITUTET PRESS OFFICE Opening hours during summer: weekdays 08-20, weekends closed. Ordinary opening hours: weekdays 08-20, weekends 09-17, local time. Emails are checked during business hours. Karolinska Institutet – a medical university. More about us on